Table 2.

Incidence and risk of events during the follow-up period per 1.0-µg/mL increase in baseline D-dimer level

Events	Incidence n (%) [95% CI]	Univariable		Multivariablec
		HR [95% CI]	P value	HR [95% CI]	P value
Symptomatic VTE	47 (0.5) [0.4–0.7]	1.04 [1.02–1.05]	<0.001	1.03 [1.00–1.05]	0.018
Incidental VTE requiring treatment	116 (1.3) [1.1–1.5]	1.03 [1.02–1.04]	<0.001	1.02 [1.01–1.04]	0.008
Composite VTEa	153 (1.7) [1.4–2.0]	1.03 [1.02–1.04]	<0.001	1.02 [1.01–1.04]	0.005
Cerebral infarction/TIA/SEE	72 (0.8) [0.6–1.0]	1.04 [1.03–1.05]	<0.001	1.04 [1.02–1.05]	<0.001
Bleedingb	127 (1.4) [1.2–1.7]	1.04 [1.02–1.05]	<0.001	1.01 [0.99–1.03]	0.359
All-cause death	1157 (12.8) [12.1–13.5]	1.05 [1.04–1.05]	<0.001	1.03 [1.02–1.03]	<0.001

CI confidence interval; ECOG PS Eastern Cooperative Oncology Group performance status; HR hazard ratio; SEE systemic embolic events; TIA transient ischemic attack; VTE venous thromboembolism

^aA composite of symptomatic VTE events and incidental VTE events requiring treatment

^bIncluded major bleeding and clinically relevant non-major bleeding events

^cAdjusted by stage (I/IB/II, III, IV), age (<65, ≥65 years), renal function (creatinine clearance of ≤50, >50 mL/min), ECOG PS (0, 1, 2), VTE at baseline (yes, no)